INCY Incyte Corp

Price (delayed)

$100.50

Market cap

$22.01B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.56

Enterprise value

$20.56B

Sector: Healthcare
Industry: Biotechnology

Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware. The company was founded in Palo Alto, California in 1991 and went public in 1993. Incyte has one drug, ...

Highlights

Incyte's revenue has increased by 17% YoY and by 2.9% from the previous quarter
INCY's gross profit is up by 17% year-on-year and by 2.9% since the previous quarter
INCY's net income has dropped by 183% year-on-year and by 75% since the previous quarter
INCY's EPS has shrunk by 182% YoY and by 75% QoQ

Key stats

What are the main financial stats of INCY
Market
Shares outstanding
219M
Market cap
$22.01B
Enterprise value
$20.56B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
9.19
Price to sales (P/S)
8.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.37
Earnings
Revenue
$2.46B
EBIT
-$271.96M
EBITDA
-$219.98M
Free cash flow
-$265.56M
Per share
EPS
-$1.56
Free cash flow per share
-$1.21
Book value per share
$10.93
Revenue per share
$11.23
TBVPS
$13.59
Balance sheet
Total assets
$3.31B
Total liabilities
$916.6M
Debt
$46.73M
Equity
$2.39B
Working capital
$1.55B
Liquidity
Debt to equity
0.02
Current ratio
3.56
Quick ratio
3.45
Net debt/EBITDA
6.61
Margins
EBITDA margin
-9%
Gross margin
94.8%
Net margin
-13.6%
Operating margin
-12.6%
Efficiency
Return on assets
-10.5%
Return on equity
-14.4%
Return on invested capital
-29.8%
Return on capital employed
-10.1%
Return on sales
-11.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

INCY stock price

How has the Incyte stock price performed over time
Intraday
2.67%
1 week
10.98%
1 month
15.03%
1 year
30.96%
YTD
15.54%
QTD
15.54%

Financial performance

How have Incyte's revenue and profit performed over time
Revenue
$2.46B
Gross profit
$2.33B
Operating income
-$309.99M
Net income
-$334.54M
Gross margin
94.8%
Net margin
-13.6%
INCY's net income has dropped by 183% year-on-year and by 75% since the previous quarter
Incyte's operating income has plunged by 175% YoY and by 68% from the previous quarter
The net margin has dropped by 171% year-on-year and by 70% since the previous quarter
INCY's operating margin has dropped by 164% year-on-year and by 64% since the previous quarter

Growth

What is Incyte's growth rate over time

Valuation

What is Incyte stock price valuation
P/E
N/A
P/B
9.19
P/S
8.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.37
INCY's EPS has shrunk by 182% YoY and by 75% QoQ
The stock's price to book (P/B) is 53% less than its 5-year quarterly average of 19.5 but 11% more than its last 4 quarters average of 8.3
INCY's P/S is 27% below its 5-year quarterly average of 12.2 but 8% above its last 4 quarters average of 8.3
Incyte's revenue has increased by 17% YoY and by 2.9% from the previous quarter

Efficiency

How efficient is Incyte business performance
The ROE has plunged by 177% YoY and by 76% from the previous quarter
INCY's return on assets has dropped by 175% year-on-year and by 72% since the previous quarter
INCY's ROS has shrunk by 154% YoY and by 122% QoQ
The ROIC has plunged by 152% YoY and by 116% from the previous quarter

Dividends

What is INCY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INCY.

Financial health

How did Incyte financials performed over time
The company's quick ratio fell by 30% YoY and by 4.7% QoQ
The current ratio has contracted by 29% YoY and by 4.6% from the previous quarter
The debt is 98% smaller than the equity
The debt is down by 10% since the previous quarter and by 8% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.